Aclarubicin is a drug that is also known as an anthracycline, a cytotoxic anti-infective agent, and restrains RNA synthesis through intercalation. It is used in the treatment of cancers.
Recent studies are undergoing on treating patients with retinal vasculopathy with cerebral leukodystrophy (RVCL), a genetic disease that is rare to happen with no specific treatment. These studies have attributed the disorder to a mutation in the tail end of a major deoxyribonucleic acid (DNA) repair enzyme. This causes the expression of a truncated and mislocalized protein. It is also said to be inherited, with symptoms showing up during middle age and affecting the eye and the brain. This is an autosomal dominant disease that affects any gender. If one has this condition, each of his or her children will be having a 50/50 chance of acquiring the gene. Theories concentrating on mouse models of RVCL and on in-vitro studies using the cells of humans are also done by the investigators. Aclarubicin is clinically tested to patients with RVCL are on process also. Some tests should be done every six months to monitor clinical response.